Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

Inclusion Criteria: * Korean prostate cancer over 50 years old with pathological confirmation * Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting. * Patients measured bone density level before starting to receive hormone therapies above. Exclusion Criteria: * Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.0. * Patients who are hard to be analysed by attach to other bone disease. * Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.